Two Sigma Advisers
CHRS icon

Two Sigma Advisers’s Coherus Oncology CHRS Stock Holding History

Two Sigma Advisers’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-307,600
Closed -$437K – 421
2025
Q4 		$437K Buy
307,600
+295,100
+2,361% +$430K ﹤0.01% 1834
2025
Q3 		$20.5K Buy
+12,500
New +$13.9K ﹤0.01% 2299
2024
Q4 		– Sell
-249,600
Closed -$260K – 2362
2024
Q3 		$260K Buy
249,600
+38,000
+18% +$52.1K ﹤0.01% 1971
2024
Q2 		$366K Buy
211,600
+4,500
+2% +$9.06K ﹤0.01% 1997
2024
Q1 		$495K Sell
207,100
-27,000
-12% -$66.4K ﹤0.01% 1872
2023
Q4 		$780K Buy
234,100
+208,400
+811% +$558K ﹤0.01% 1746
2023
Q3 		$96.1K Sell
25,700
-44,500
-63% -$206K ﹤0.01% 2213
2023
Q2 		$300K Sell
70,200
-24,100
-26% -$142K ﹤0.01% 1982
2023
Q1 		$645K Sell
94,300
-122,500
-57% -$951K ﹤0.01% 1835
2022
Q4 		$1.72M Buy
216,800
+40,200
+23% +$309K ﹤0.01% 1315
2022
Q3 		$1.7M Buy
176,600
+75,200
+74% +$761K ﹤0.01% 1252
2022
Q2 		$734K Buy
101,400
+24,800
+32% +$216K ﹤0.01% 1747
2022
Q1 		$989K Buy
+76,600
New +$974K ﹤0.01% 1643
2020
Q3 		– Sell
-235,200
Closed -$4.2M – 2425
2020
Q2 		$4.2M Sell
235,200
-123,900
-35% -$2.1M 0.01% 866
2020
Q1 		$5.83M Sell
359,100
-33,600
-9% -$621K 0.02% 655
2019
Q4 		$7.07M Buy
392,700
+133,400
+51% +$2.46M 0.02% 713
2019
Q3 		$5.25M Buy
259,300
+68,100
+36% +$1.36M 0.01% 741
2019
Q2 		$4.23M Buy
191,200
+150,900
+374% +$2.62M 0.01% 898
2019
Q1 		$550K Buy
40,300
+8,900
+28% +$119K ﹤0.01% 1757
2018
Q4 		$284K Sell
31,400
-11,700
-27% -$135K ﹤0.01% 2010
2018
Q3 		$711K Buy
43,100
+6,500
+18% +$115K ﹤0.01% 1651
2018
Q2 		$512K Buy
+36,600
New +$524K ﹤0.01% 1906
2017
Q1 		– Sell
-23,700
Closed -$667K – 2349
2016
Q4 		$667K Buy
23,700
+13,100
+124% +$367K ﹤0.01% 1730
2016
Q3 		$284K Buy
+10,600
New +$289K ﹤0.01% 1898

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Two Sigma Advisers's CHRS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Coherus Oncology (CHRS) in Q1 2026, closing a stake of 307,600 shares — an estimated $437K sold.

Two Sigma Advisers first reported a position in CHRS in Q3 2016 and held it in 24 quarters. The position peaked at $7.07M in Q4 2019. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Coherus Oncology position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 307,600 Coherus Oncology shares in Q1 2026, an estimated $437K.
  • Two Sigma Advisers first reported a position in Coherus Oncology in Q3 2016 and held it in 24 quarters.
  • Two Sigma Advisers's Coherus Oncology position peaked at $7.07M in Q4 2019.
  • 158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.